Esser, S. et al: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study.

Zurück zur Übersicht

18.-21.10.2023 / EACS 2023

Studiensammlung zu HIV

Protopapas, K. et al: Public Awareness towards the U=U Statement A Multi-Country Survey (Austria, Greece and Switzerland)

22.-26.07.2024 / IAS

Miralles, C. et al: Switching to B/F/TAF in a Real-World Cohort of Older People with HIV and a High Burden of Non-AIDS related comorbities

22.-26.07.2024 / IAS

Avihingsanon, A. et al: Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV

03.-06.03.2024 / CROI

Sabranski, M. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort.

18.-21.10.2023 / EACS 2023

Schellberg, S. et al: Three-Year B/F/TAF Use in Treatment-Naive and Treatment-Experienced People Living With HIV in the BICSTaR Cohort Study

23.-25.03.2023 / DÖAK

Stephan, C. et al: Longer-Term (3-Year) Effectiveness and Safety of B/F/TAF for the Treatment of HIV in the German BICSTaR Cohort

23.-25.03.2023 / DÖAK

Avihingsanon, A. et al: Predictors of Hepatitis B treatment response in people with HIV-1/HBV coinfection

19.-22.02.2023 / CROI

Ogbuagu, O. et al: Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH

19.-23.02.2023 / CROI

Chastek, B. et al: ART Regimen Persistence Among Treatment-Experienced Patients With HIV Switching to a MTR or STR Since 2018

23.-26.10.2022 / HIV Drug Therapy 2022

Trottier, B. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study

23.-26.10.2022 / HIV Drug Therapy 2022